PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.
David G. Perryman, President and CEO, Zirus, Inc.
I just want to thank you again for the wonderful job you did for Zirus in designing our award winning animation on viral replication. If it was just how the animation looked and was received by others, you would be great. But what mattered more was how you became trusted partners with us in helping us create value and spreading our message. You have been invaluable to Zirus and we very much appreciate your contributions, talents and professionalism.